

Clinical trials of Indobufen

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
Indobufen vs warfarin			
SIFA , 1997 [NCT00244426] n=462/454 follow-up: 12 months	indobufen 200 mg (the dose was lowered to 100 mg if impaired renal function:cc<80 ml/mn) versus warfarin standard dose(target INR 2.0-3.5)	non rheumatismal AF and recent cerebral ischemic episode(<or =15 days)	Parallel groups Open Italy

More details and results :

- antithrombotics for atrial fibrillation in secondary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q392>

References

SIFA, 1997:

Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, Coccheri S Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997 May;28:1015-21 [[9158644](#)]